Management of BRAF Mutated Lung Cancer

Speaker: Oliver Gautschi

Oliver Gautschi describes a small population of BRAF mutated lung adenocarcinoma, activating and non-activating BRAF mutations and opportunities with BRAF inhibition drawn from the experiences in melanoma treatment. He explains the results of the EURAF study in lung cancer patients.

Discussion Points

  • BRAF mutations in lung adenocarcinoma
  • Targeted therapies for lung adenocarcinoma: recent patient cases
  • Final results of EURAF cohort study

Abstracts Discussed

Abstract 98O_PR - Targeted therapy for BRAF-mutant lung cancer: Results from the European EURAF cohort study